Capecitabine Tablet, Film Coated
Product Images NDC 31722-775

9 FDA label images from Camber Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 31722-775). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Capecitabinetabletsstructure (Capecitabinetabletsstructure)

Capecitabinetabletsstructure (Capecitabinetabletsstructure)
Chemical structure diagram depicting the molecular formula of capecitabine, the active ingredient in the product. The diagram shows the arrangement of atoms and bonds consistent with the capecitabine molecule.*
FDA Label Image

Capecitabinetabletsfigure1 (Capecitabinetabletsfigure1)

Capecitabinetabletsfigure1 (Capecitabinetabletsfigure1)
A Kaplan-Meier survival curve comparing two treatment groups: CAPECITABINE (solid line) and 5-FU + LEUCOVORIN (dashed line). The y-axis represents survival probability, ranging from 0 to 1, and the x-axis shows months since randomization from 0 to 96. The graph includes a table indicating the number of patients at risk for each group at various time points.*
FDA Label Image

Capecitabinetabletsfigure2 (Capecitabinetabletsfigure2)

Capecitabinetabletsfigure2 (Capecitabinetabletsfigure2)
A survival curve chart comparing two treatment groups over months since randomization: Capecitabine and 5-FU + Leucovorin. The Y-axis represents survival probability from 0 to 1.0, and the X-axis shows time in months up to 96. A table below lists the number of patients at risk for each group at various time points.*
FDA Label Image

Capecitabinetabletsfigure3 (Capecitabinetabletsfigure3)

Capecitabinetabletsfigure3 (Capecitabinetabletsfigure3)
A line graph showing estimated probability over time (days) comparing two groups: 5-FU + Leucovorin (Mayo Regimen) and Capecitabine 1250 mg/sqm twice daily intermittent. The y-axis represents estimated probability from 0.0 to 1.0, and the x-axis represents time up to 1500 days. The graph includes a marked point near 391-392 days on the x-axis.*
FDA Label Image

Capecitabinetabletsfigure4 (Capecitabinetabletsfigure4)

Capecitabinetabletsfigure4 (Capecitabinetabletsfigure4)
A Kaplan-Meier survival probability graph comparing Docetaxel 100 mg/sqm every 3 weeks versus Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks. The y-axis shows estimated probability from 0 to 1, and the x-axis shows time in days up to 800 days.*
FDA Label Image

Apecitabinetabletsfigure5 (Capecitabinetabletsfigure5)

Apecitabinetabletsfigure5 (Capecitabinetabletsfigure5)
A Kaplan-Meier survival curve comparing estimated probability over time (days) between two treatment groups: Docetaxel 100 mg/sqm every 3 weeks and Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks. The graph shows survival probabilities from 0 to 800 days with respective curves for each group and markers at 351.5 and 442 days.*
FDA Label Image
FDA Label Image

Capecitabinetabletslabel150mg60s (Capecitabinetabletslabel150mg60s)

Capecitabinetabletslabel150mg60s (Capecitabinetabletslabel150mg60s)
Label for capecitabine 150 mg film-coated tablets by Camber Pharmaceuticals, Inc. Contains 60 tablets. The label includes warnings for hazardous drug handling, administration instructions, storage conditions, and contact information. Manufactured by Hetero Labs Limited, India, for Camber Pharmaceuticals in New Jersey.*
FDA Label Image

Capecitabinetabletslabel500mg60s (Capecitabinetabletslabel500mg60s)

Capecitabinetabletslabel500mg60s (Capecitabinetabletslabel500mg60s)
Label for Capecitabine Tablets, USP 500 mg by Camber Pharmaceuticals, Inc. The label indicates 60 film-coated tablets per container. It includes warnings that capecitabine is a hazardous and cytotoxic agent, dosing instructions advising to swallow tablets whole within 30 minutes of a meal, and storage conditions at 20° to 25°C. Manufacturer information lists Hetero Labs Limited, India, for Camber Pharmaceuticals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.